Torrent Pharmaceuticals Ltd. Q4 FY2024 results: revenue ₹2,745 crore, up 10.2% on the year

Torrent Pharmaceuticals Ltd. (TORNTPHARM) reported consolidated revenue from operations of ₹2,745 crore for Q4 FY2024, the quarter ended 31 March 2024, up 10.2% on the same quarter a year earlier. Profit after tax was ₹449 crore, up 56.4% on the year, and earnings per share ₹13.27. The figures are the company's own, from the audited results it filed with NSE on 24 May 2024.

Revenue from operations₹2,745 croreup 10.2%

Profit after tax₹449 croreup 56.4%

EPS₹13.27

QuarterQ4 FY2024ended 31 March 2024

The quarter, against the one before and a year earlier

Line	Q4 FY2024	Q3 FY2024	A year earlier	Change on the year
Revenue from operations	2,745	2,732	n/a	n/a
Other income	31	-33	n/a	n/a
Total income	2,776	2,699	n/a	n/a
Cost of materials consumed	410	379	n/a	n/a
Purchases of stock-in-trade	315	327	n/a	n/a
Changes in inventories	-46	-9	n/a	n/a
Employee benefit expense	486	496	n/a	n/a
Finance costs	80	80	n/a	n/a
Depreciation, depletion and amortisation	203	213	n/a	n/a
Other expenses	697	670	n/a	n/a
Total expenses	2,145	2,156	n/a	n/a
Profit before exceptional items and tax	631	543	n/a	n/a
Exceptional items	0	88	n/a	n/a
Profit before tax	631	631	n/a	n/a
Current tax	142	106	n/a	n/a
Deferred tax	40	82	n/a	n/a
Total tax	182	188	n/a	n/a
Profit after tax	449	443	n/a	n/a
Attributable to owners of the parent	449	442	n/a	n/a
Other comprehensive income	1	-1	n/a	n/a
Total comprehensive income	450	442	n/a	n/a
EPS, basic	₹13.27	₹13.10	n/a	n/a
EPS, diluted	₹13.27	₹13.10	n/a	n/a

₹ crore except per share.

Quarterly results, the last 12 quarters

	Q2 FY2024	Q3 FY2024	Q4 FY2024	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025	Q1 FY2026	Q2 FY2026	Q3 FY2026	Q4 FY2026	Q1 FY2027
Sales	2,660	2,732	2,745	2,859	2,889	2,809	2,959	3,178	3,302	3,303	4,197	4,921
Expenses	2,127	2,156	2,145	2,227	2,212	2,151	2,252	2,403	2,471	2,466	3,585	4,155
Operating profit	825	869	883	904	939	914	964	1,032	1,083	1,088	1,356	1,664
OPM %	31%	32%	32%	32%	33%	33%	33%	32%	33%	33%	32%	34%
Other income	26	-33	31	24	-16	33	-18	-37	-27	-13	-17	-12
Interest	91	80	80	75	64	57	56	56	48	45	236	305
Depreciation	201	213	203	197	198	199	201	201	204	206	508	593
Exceptional items	0	88	0	0	0	0	-24	0	-13	-10	-66	-21
Profit before tax	559	631	631	656	661	691	665	738	791	814	529	733
Tax %	31%	30%	29%	30%	31%	27%	25%	26%	25%	22%	31%	23%
Net profit	386	443	449	457	453	503	498	548	591	635	364	566
EPS in ₹	₹11.39	₹13.10	₹13.27	₹13.51	₹13.37	₹14.88	₹14.71	₹16.19	₹17.45	₹18.77	₹11.51	₹14.87
Filing	NSE	NSE	NSE	NSE	NSE	NSE	Filing	Filing	Filing	Filing	Filing	Filing

₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company.

Source

Audited consolidated results for the quarter ended 31 March 2024, filed with NSE on 24 May 2024: the result statement. All of Torrent Pharmaceuticals Ltd.'s results: NSE company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install